Derbyshire Medicines Management and Clinical Policies
RED: NHSE commission a new combined pertuzumab and trastuzumab subcutaneous injection, brand name PHESGO®, for all existing pertuzumab and trastuzumab indications as an alternative to IV pertuzumab and trastuzumab. (Decison date - March 2021)
DNP: For use in combination with chemotherapy in the neoadjuvant treatment of adults with HER2 positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence, adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence, and in combination with docetaxel in adults with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. (Decison date - March 2021)
